Thanks just bought another 2k pre market she is going to run hard you can make book on that.
most undervalued gene editing platform AI computational application for green industrial & green agriculture including cannabis, fruits vegetables insects. And Biotech Biotech subsidiary Biomica Proof of concept, first-in-man study – Immuno-oncology program. https://www.biomicamed.com/
EVGN Biomica microbiome-based therapeutics for immunology looks superior to Seres Therapeutics technology 2.5 billion company that went from 2.52-38.00
Seres therapeutics 2.4 billion market cap. EVGN Biomica 200 million market cap. EVGN has the superior tech look for a monster move into double digit dollars coming soon.
EVGN Subsidiaries: Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
Genome Stocks-Gene Editing. $PACB 6.2 billion market cap $BEAM 5.4 billion market cap $CRSP 13 billion market cap $EDIT 4.8 billion market cap $SGMO 2.3 billion market cap $NTLA 4.8 billion market cap $BLUE 3.3 billion market cap $BNGO 1.2 billion market cap $EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.